<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01455103</url>
  </required_header>
  <id_info>
    <org_study_id>CA210-002</org_study_id>
    <nct_id>NCT01455103</nct_id>
  </id_info>
  <brief_title>Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma</brief_title>
  <acronym>PD-L1</acronym>
  <official_title>A Phase I Study of the Biologic Effects of BMS-936559 Treatment in Subjects With Unresectable Stage III or IV Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate pharmacodynamic changes of BMS-936559 treatment on
      the biomarkers measured in the peripheral blood and tumor tissues of subjects with
      unresectable Stage III or IV Melanoma.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">November 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evidence of immunomodulatory effects of BMS-936559 as measured by changes from baseline in biomarkers assessed 1) peripheral blood assays including flow cytometry and soluble factors and 2) tumor based assays including immunohistochemistry</measure>
    <time_frame>Baseline and within the first 24 weeks of study participation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of BMS-936559 as measured by the incidence of adverse events (AEs), serious AEs, laboratory test abnormalities, and changes in vital signs</measure>
    <time_frame>Every 2 weeks until 70 days after last treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor Activity of BMS-936559 as measured by the objective response rate, disease control rate, duration of response, and progression free survival</measure>
    <time_frame>Every 6 weeks for 1 year, every 12 weeks thereafter until confirmed disease progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of BMS-936559 as measured by the frequency of subjects with an increase in anti-drug antibody levels from baseline</measure>
    <time_frame>Baseline, Week 6, Week 12, and then every 12 weeks until follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic activity of BMS-936559 as measured by changes from baseline of the tetramer assay in HLA-A*0210 positive subject only</measure>
    <time_frame>Predose (screening) and Cycle 3 Day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Stage III or IV Melanoma</condition>
  <arm_group>
    <arm_group_label>Arm 1: BMS-936559 (1mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: BMS-936559 (3mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: BMS-936559 (10mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMS-936559 (Anti-PD-L1)</intervention_name>
    <description>Solution, Intravenous infusion, 1 mg/kg, Every 2 weeks, Up to 2 years, depending on response</description>
    <arm_group_label>Arm 1: BMS-936559 (1mg/kg)</arm_group_label>
    <other_name>MDX1105</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMS-936559 (Anti-PD-L1)</intervention_name>
    <description>Solution, Intravenous infusion, 3 mg/kg, Every 2 weeks, Up to 2 years, depending on response</description>
    <arm_group_label>Arm 2: BMS-936559 (3mg/kg)</arm_group_label>
    <other_name>MDX1105</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMS-936559 (Anti-PD-L1)</intervention_name>
    <description>Solution, Intravenous infusion, 10 mg/kg, Every 2 weeks, Up to 2 years, depending on response</description>
    <arm_group_label>Arm 3: BMS-936559 (10mg/kg)</arm_group_label>
    <other_name>MDX1105</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women â‰¥ 18 years

          -  Eastern Cooperative Oncology Group (ECOG) status = 0 to 1

          -  Subjects with unresectable Stage III or IV Melanoma who are either refractory or
             intolerant to, or have refused standard therapy for treatment of metastatic Melanoma

          -  Subject must have histologic or cytologic confirmation of advanced Melanoma

          -  Subjects must have at least one measurable lesion at baseline by computed tomography
             (CT) or magnetic resonance imaging (MRI) as per Response Evaluation Criteria in Solid
             Tumors (RECIST) 1.1 criteria

          -  Subjects must have at least 1 tumor site that can be biopsied at acceptable clinical
             risk and must consent to pre- and post-treatment biopsies

        Exclusion Criteria:

          -  Active or progressing brain metastases

          -  Other concomitant malignancies (with some exceptions per protocol)

          -  Active or history of autoimmune disease

          -  Positive test for human immunodeficiency virus (HIV) 1&amp;2 or known acquired
             immunodeficiency syndrome (AIDS)

          -  History of any hepatitis

          -  Prior therapy with any antibody/drug that targets the T cell coregulatory proteins,
             including but not limited to, anti Programmed cell death 1 (PD-1), anti Programmed
             cell death ligand 1 (anti-PD-L1), anti-PD-L2, anti-CD137, anti-OX-40, anti-CD40 or
             anti Cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA-4) antibodies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2011</study_first_submitted>
  <study_first_submitted_qc>October 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2011</study_first_posted>
  <last_update_submitted>December 12, 2011</last_update_submitted>
  <last_update_submitted_qc>December 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

